Taken together, our findings highlight several proteins that are closely associated with early HER2-inhibitor response, complementary studies need to be conducted to validate the importance of our findings and this could have implication for new strategies to improve the efficacy of breast-cancer treatment. This evidence concerns the gene ERBB2 and breast carcinoma.